



ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA

ARCHIVIO ISTITUZIONALE
DELLA RICERCA

Alma Mater Studiorum Università di Bologna Archivio istituzionale della ricerca

Sequential Combination of Cognitive-Behavioral Treatment and Well-Being Therapy in Depressed Patients with Acute Coronary Syndromes: A Randomized Controlled Trial (TREATED-ACS Study)

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

Rafanelli C., Gostoli S., Buzzichelli S., Guidi J., Sirri L., Gallo P., et al. (2020). Sequential Combination of Cognitive-Behavioral Treatment and Well-Being Therapy in Depressed Patients with Acute Coronary Syndromes: A Randomized Controlled Trial (TREATED-ACS Study). *PSYCHOTHERAPY AND PSYCHOSOMATICS*, 89(6), 345-356 [10.1159/000510006].

Availability:

This version is available at: <https://hdl.handle.net/11585/803582> since: 2024-05-21

Published:

DOI: <http://doi.org/10.1159/000510006>

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).
When citing, please refer to the published version.

(Article begins on next page)

1 **Sequential combination of cognitive-behavioral treatment and Well-Being**

2 **Therapy in depressed patients with acute coronary syndromes.**

3 **A randomized controlled trial (TREATED-ACS Study)**

4
5 Chiara Rafanelli^{a*}, Sara Gostoli^a, Sara Buzzichelli^b, Jenny Guidi^a, Laura Sirri^a, Pamela Gallo^c, Enrica
6 Marzola^b, Serena Bergerone^d, Gaetano Maria De Ferrari^d, Renzo Roncuzzi^e, Giuseppe Di Pasquale^c,
7 Giovanni Abbate Daga^b, Giovanni A. Fava^f

8
9 ^aDepartment of Psychology, University of Bologna, Bologna, Italy

10 ^b Eating Disorders Center for Treatment and Research, Department of Neuroscience, University of
11 Turin, Turin, Italy

12 ^c Division of Cardiology, Maggiore Hospital, Bologna, Italy

13 ^d Division of Cardiology, Internal Medicine Department, Città della Salute e della Scienza, University
14 of Turin, Turin, Italy

15 ^e Division of Cardiology, Bellaria Hospital, Bologna, Italy

16 ^f Department of Psychiatry, University at Buffalo, Buffalo NY, U.S.A.

17
18 **Short title:** Sequential combination of CBT and WBT in depressed ACS patients

19
20 *** Corresponding Author**

21 Chiara Rafanelli

22 Department of Psychology

23 University of Bologna

24 Viale Berti Pichat 5

25 40127 Bologna

26 Italy

1 Tel: +39 051 2091847

2 Fax: +39 051 243086

3 Email: chiara.rafanelli@unibo.it

4

5 **Keywords:** Acute coronary syndrome; cognitive-behavioral therapy; depression; sequential
6 treatment; well-being therapy.

1 **Abstract**

2

3 **Introduction:** Randomized controlled trials (RCT) of psychotherapeutic interventions have addressed
4 depression and demoralization associated with Acute Coronary Syndromes (ACS). The present trial
5 introduces psychological well-being, an increasingly recognized factor in cardiovascular health, as a
6 therapeutic target. **Objective:** This study was designed to determine whether the sequential
7 combination of Cognitive-Behavioral Therapy (CBT) and Well-Being Therapy (WBT) may yield
8 more favorable outcomes than an active control group (Clinical Management, CM) and to identify
9 subgroups of patients at greater risk for cardiac negative outcomes. **Methods:** This multicenter RCT
10 compared CBT/WBT sequential combination versus CM, with up to 30-month follow-up. One
11 hundred consecutive depressed and/or demoralized patients (out of 740 initially screened by
12 cardiologists after a first episode of ACS) were randomized to CBT/WBT associated with lifestyle
13 suggestions (N= 50) and CM (N= 50). Main outcome measures included severity of depressive
14 symptoms according to the Clinical Interview for Depression, changes in subclinical psychological
15 distress, well-being and biomarkers; medical complications and events. **Results:** CBT/WBT
16 sequential combination was associated with a significant improvement in depressive symptoms
17 compared to CM. In both groups, benefits persist at follow-up, even though differences faded.
18 Treatment was also related to significant amelioration of biomarkers (platelet count, HDL, d-dimer),
19 whereas the two groups showed similar frequencies of adverse cardiac events. **Conclusions:**
20 Addressing psychological well-being in the psychotherapeutic approach to ACS patients with
21 depressive symptoms was found to entail important clinical benefits. It is argued that lifestyle changes
22 geared to cardiovascular health may be facilitated by a personalized approach that targets well-being.

23

24 *Trial registration:* ClinicalTrials.gov NCT00998400 (October 20, 2009),
25 <https://clinicaltrials.gov>

26

1 **Introduction**

2
3 There is extensive evidence that the presence of depressive symptoms in Acute Coronary
4 Syndromes (ACS) is associated with poor therapeutic adherence, higher frequency of relapses and
5 increased mortality [1]. Mood disturbances may consist of major or minor depressive episodes,
6 chronic depression, and demoralization [1-3], which is characterized by a sense of subjective
7 incompetence [4].

8 The relationship of depression to ACS has generated the hypothesis that treatment of mood
9 disturbances may yield improved medical and psychological outcomes. A number of randomized
10 controlled trials have indicated the effectiveness of antidepressant drugs compared to placebo in
11 relieving depression, yet a favorable effect on cardiovascular events was not detected [1] or could not
12 be generalized [5]. Similar findings have been reported for the application of Cognitive-Behavioral
13 Therapy (CBT) to ACS [6], pioneered by the ENRICH trial [7].

14 Psychotherapeutic approaches, however, have been mainly shifted on the side of psychological
15 dysfunction and have neglected psychological well-being. There is increasing evidence on the role of
16 positive psychological assets on lifestyle and cardiovascular health [8].

17 In this trial, the sequential use of distress and well-being psychotherapeutic strategies was
18 selected. The first phase of treatment (CBT) was concerned with distress associated with
19 hospitalization and medical events. In the second phase, Well-Being Therapy (WBT), a specific
20 psychotherapeutic approach for modulating psychological well-being [9], was introduced and
21 suggestions for lifestyle modifications geared to cardiovascular health were provided [10]. The
22 sequential combination of CBT and WBT has been found to yield enduring clinical benefits in the
23 setting of psychiatric disorders [9-10], with particular reference to recurrent depression [11].

24 The aim of the trial was to evaluate the efficacy of the sequential combination of CBT and
25 WBT, compared to clinical management (CM), as to depressive symptoms (primary outcome),
26 psychological distress, well-being, as well as cardiovascular events, biomarkers and mortality

1 (secondary outcomes), both after treatment and up to 30-month follow-up. The identification of
2 subgroups of patients at greater risk for cardiac negative outcomes was included.

3

4 **Methods**

5

6 *Sample*

7 Participants were patients hospitalized for a first episode of acute myocardial infarction or
8 unstable angina at the Cardiology Divisions of Maggiore Hospital (Bologna) and Molinette Hospital
9 (Torino). Myocardial infarction was documented by cardiac symptoms (presence of acute chest,
10 epigastric, neck, jaw, or arm pain or discomfort or pressure without apparent non-cardiac source) and
11 signs (acute congestive heart failure or cardiogenic shock in the absence of non-CHD causes),
12 associated with ECG findings (characteristic evolutionary ST-T changes or new Q waves) and/or
13 cardiac biomarkers (blood measures of myocardial necrosis, specifically CK, CK-MB, CK-MBm, or
14 troponin, cTn). Instable angina was documented by cardiac symptoms (chest pain lasting less than 20
15 minutes) with likely ECG findings (ST-segment depression and abnormal T-wave) in absence of
16 myocardial necrosis biomarkers.

17 Medically eligible patients underwent a psychological evaluation by two clinical psychologists
18 with expertise in the field of psychosomatic aspects of cardiovascular diseases about 30 days after
19 ACS. Inclusion criteria were: current diagnosis of major/minor depression or dysthymia according to
20 DSM-IV-TR [12] and/or demoralization according to DCPR criteria [13]. The study was approved
21 from the institutional review board of the Ethics Committee in both centers (identifier: Studio CE
22 09058). Written informed consent was secured from all patients, for both initial psychological
23 evaluation and trial participation, after the procedures ~~were~~ had been fully explained to them.
24 Participants did not receive any compensation. Exclusion criteria included a positive history of
25 bipolar disorder (DSM-IV-TR), major depression with psychotic features, positive history of

1 substance abuse/dependence during the previous 12 months, suicide risk, current use of
2 antidepressants and/or psychotherapy.

3 Psychological evaluation was performed in 288 patients with a first episode of ACS and the
4 first 100 depressed and/or demoralized consecutive patients were enrolled (Fig. 1).

5

6 *Assessment*

7 *Medical variables.* Data on ACS, traditional cardiac risk factors (smoking habit, hypertension,
8 dyslipidemia, family history of cardiovascular disease, diabetes mellitus, left ventricular ejection
9 fraction < 40), medications and comorbidities were collected from medical records. The cardiologists
10 involved in the study evaluated the patients at intake and once every 6 months to monitor changes in
11 the clinical course of cardiac disease. Data from electrocardiogram, echocardiogram, X-ray, blood
12 pressure and blood samples (cholesterol levels, creatinine, glycosylated hemoglobin, C-reactive
13 protein, coagulation/fibrinolysis biomarkers) were provided at intake. The Global Registry of Acute
14 Coronary Events (GRACE) risk index [14] was calculated during hospital admission for ACS to
15 determine both in-hospital and 6-month post-discharge risk of morbidity and mortality. From the
16 beginning of the psychological treatment and up to 30-month follow-up after the end of the
17 intervention, information about cardiac negative outcomes, such as re-hospitalizations due to cardiac
18 complications, acute myocardial infarction, unstable angina, angioplasty, cardiac surgery, and cardiac
19 mortality after the first ACS, were collected.

20 *Psychological variables.* Psychological assessment included both observer-rated and self-
21 reported measures, before the beginning of the interventions (baseline, pre-treatment), at the end
22 (post-treatment), and 3, 6, 12 and 30 months after the end of treatment. The Structured Clinical
23 Interview for DSM-IV-TR, Axis I Disorders [15], was used to investigate the presence of major/minor
24 depression and dysthymia. The Semi-Structured Interview based on the Diagnostic Criteria for
25 Psychosomatic Research (SSI-DCPR) [16] was administered to assess the presence of demoralization
26 [17]. This interview has shown excellent inter-rater reliability, with kappa values ranging from 0.69

1 to 0.97 [18]. The 20-item change version of the Clinical Interview for Depression (CID) [19-20], a
2 modified version of the Hamilton Rating Scale for Depression [21-22], was used to perform a
3 comprehensive assessment of affective symptoms. It contains 20 items rated on a 7-point *Likert* scale,
4 with specification of each anchor point based on severity, frequency and/or quality of symptoms. The
5 higher the score, the worse the psychological condition. CID has been shown to be a sensitive
6 assessment tool in clinical trials [20]. The Symptom Questionnaire (SQ) [23-24] is a 92-item self-
7 report questionnaire, which yields 4 main scales: “depression”, “anxiety”, “hostility-irritability” and
8 “somatization”. The higher the score, the higher the psychological distress. The Psychological Well-
9 Being scales (PWB) [25-26], an 84-item questionnaire, has been used to evaluate six psychological
10 well-being dimensions (autonomy, environmental mastery, personal growth, positive relations,
11 purpose in life, self-acceptance). Higher scores correspond to greater psychological well-being.

12

13 *Study design*

14 The study is a two-center randomized controlled trial with a longitudinal and prospective
15 design. Enrolled patients were randomly assigned to either CBT/WBT or CM and assessed at the
16 beginning, the end of CBT/WBT or CM sessions, and subsequent follow-ups up to 30 months after
17 the conclusion of the interventions. Treatment allocation was accomplished through random
18 computerized assignment that allocated 50% of patients to each treatment group, with assignments
19 concealed until the time of group assignment. Patients were assessed by two clinical psychologists,
20 who were blind as to treatment assignment, at pretreatment, post-treatment, and 3, 6, 12 and 30
21 months after the end of treatment. Both the sequential combination of CBT/WBT and the CM were
22 performed by psychotherapists who had received specific training. Both interventions consisted in 12
23 weekly, 45-minute sessions. The sequential administration of CBT (8 sessions) and WBT (4 sessions)
24 was based on a written protocol [9-10]. The WBT techniques were used to improve or balance one
25 or more of the six dimensions of psychological well-being (environmental mastery, purpose in life,
26 personal growth, autonomy, self-acceptance and positive relations with others), and were

1 supplemented with suggestions for lifestyle modification geared to cardiovascular health, including
2 treatment adherence.

3 CM entails the same amount of time and attention from a professional figure than the
4 experimental group, but specific interventions (such as exposure strategies, diary work and cognitive
5 restructuring) were proscribed [27]. Such form of active control - unlike in previous trials that used
6 treatment as usual⁵ - allows to discriminate specific and non-specific ingredients of the
7 psychotherapeutic approach. It consisted of empathic listening, reviewing patients' clinical status and
8 providing opportunities for disclosure of distress and worries, and encouragement of treatment
9 adherence.

10

11 *Statistical analyses*

12 Data were analyzed by means of SPSS 20.0 (SPSS Inc., Chicago, IL, USA). The quality of data
13 collection was monitored regularly to assure accuracy and completeness. For all tests performed,
14 significance level was set at 0.05, two-tailed. The sample size was estimated using Piface software,
15 which identified a minimum of 16 participants per arm to detect the expected superiority of
16 CBT/WBT on CM [11], with a power of 80% and a significance level of 5%. Thus, with 50 patients
17 per group we expected a "large" effect size (Cohen's $d=0.8$) [28].

18 Multivariate ANOVA was used to examine differences in dimensional psychological variables (i.e.
19 CID-20 total score, PWB and SQ scales scores) between patients assigned to CBT/WBT and CM at
20 pre-intervention.

21 Mixed-model ANOVA (Repeated Measures) was performed to test differences between groups
22 (CBT/WBT or CM) on the CID-20 total score, the PWB scales, and the SQ scale scores at different
23 follow-up evaluations. All analyses were performed by using intention-to-treat (ITT) analysis, where
24 missing values were managed by means of multiple imputations procedure. Greenhouse-Geisser
25 correction was applied when appropriate. All analyses were adjusted for cardiac illness severity (i.e.,
26 GRACE index for 6-month probability of cardiac mortality) [14].

1 Each biomarker was dichotomized around the baseline median of the sample, in order to
2 identify subgroups of patients at higher cardiovascular risk. McNemar test (applied to contingency
3 tables) was used to identify significant changes over time in the frequencies of DSM, DCPR
4 diagnoses and subgroups of patients at higher cardiovascular risk.

5 Survival analyses (Cox Regression, Kaplan-Meier) to identify cardiac events and mortality that
6 occurred between pre-treatment and 30-month follow-up were performed.

7

8 **Results**

9

10 *Baseline profile of the sample*

11 The first 100 consecutive depressed and/or demoralized patients one month after ACS were
12 enrolled, yielding 50 patients in each treatment group. The mean age of the sample was 58.8 (SD=
13 10.5) years (range: from 40 to 84 years). Participants were mainly men (69%), married (69%),
14 employed (58%) and graduated from high school (44%). No significant differences based on group
15 allocation were found (Table 1).

16 As to the cardiac profile of the sample, ST-Elevation Myocardial Infarction (STEMI) was the
17 most frequent form of ACS (66%) and almost all patients (94%) underwent percutaneous transluminal
18 coronary angioplasty (PTCA), 77% with the application of a single stent, 17% of 2 or more stents.
19 The most frequent cardiovascular risk factors registered at hospital admission were dyslipidemia
20 (58%) and hypertension (52%). No differences concerning ACS-related aspects and GRACE risk
21 scores were found comparing CBT/WBT versus CM (Table 1).

22 Among the medications prescribed at discharge, the most frequent were statins (96%), beta-
23 blockers (96%), and platelet aggregation inhibitors (96%). Patients allocated to CM were prescribed
24 significantly more frequently beta-blockers, calcium antagonists, and alpha-adrenergic receptor
25 inhibitors compared to the CBT/WBT group (Table 1). The sample presented with a number of
26 medical comorbidities; the most frequent were gastrointestinal (43%) and endocrine diseases (14%).

1 As to comorbid medical diagnoses and levels of biomarkers assessed at baseline, the two groups did
2 not show any significant difference (Table 1). From the psychological point of view, the most frequent
3 diagnosis was demoralization (91%), followed by minor depression (56%). The two groups did not
4 show any statistical difference, except for PWB “personal growth” scores ($F= 4.45$; $df= 1, 98$; $p=$
5 0.038) and frequency of depression/demoralization comorbidity ($\chi^2= 4.86$; $df= 1$; $p= 0.028$), that were
6 significantly higher among the CBT/WBT patients (Table 1).

7

8 *Pre/post intervention modifications*

9 *Psychological variables.* Forty-eight patients completed the CBT/WBT treatment, and 48
10 patients attended CM sessions. Two patients in each group early dropped-out, mainly for lack of
11 interest or motivation. Forty and 38 patients, respectively, completed follow-up evaluations (Fig. 1).

12 As to the CID-20 total score, a significant interaction between group allocation and time was
13 found ($F= 2.75$; $df= 3.85$; $p< 0.05$) (Table 2). Significant decreases in symptoms scores from pre- to
14 post-treatment were found in both CBT/WBT ($p< 0.001$) and CM ($p< 0.01$) groups. However, the
15 effect sizes for score modifications were strong in the CBT/WBT treatment group (Cohen’s $d= 1.161$
16 and 1.393 , respectively) and weak/medium among CM patients (Cohen’s $d= 0.492$ and 0.589 ,
17 respectively) (Table 2). Patients allocated to CBT/WBT reported significant lower scores at post-
18 treatment ($p= 0.040$) compared to CM. Starting from the 3-month follow-up, CID-20 score
19 differences between the two groups were no longer significant. Benefits, however, tended to persist
20 in both groups.

21 No significant interactions were found between time and group allocation as to SQ and PWB
22 mean scores, except for hostility as assessed by the SQ ($F= 3.12$; $df= 4.29$; $p< 0.05$), with CM group
23 showing significantly higher scores at 6-month follow-up than CBT/WBT ($p= 0.039$) (Table 2).

24 *Biomarkers.* At 3-month post-intervention follow-up, we observed a significant reduction of
25 the frequencies of patients with biomarkers’ levels considered to be at risk (below or above the
26 median), only among patients allocated to CBT/WBT group. In particular, we found a significant

1 decrease of the cases with high platelet count (from 52% to 36%, $p < 0.05$; median= 226 $10^3/mm^3$),
2 lower HDL cholesterol (from 52% to 34%, $p < 0.05$; median= 47 mg/dL) and higher D-dimer (from
3 56% to 40%, $p < 0.05$; median= 0.31 mg/LFEU) in patients assigned to CBT/WBT compared to those
4 receiving CM. No significant decrease in patients with risky levels of biomarkers was observed in the
5 CM group.

6

7 *Survival analyses*

8 Within 36 months from baseline, 15% of the total sample had an adverse cardiac outcome. As
9 to cardiac morbidity and mortality, we did not find any significant difference between CBT/WBT and
10 CM groups in terms of survival. Indeed, among patients allocated to CBT/WBT, 16% (N= 8) had
11 non-fatal cardiac events and one patient (2%) had a cardiac death (occurring after 18 months from
12 baseline), whereas among CM patients, 10% (N= 5) had non-fatal events and one patient (2%) had a
13 cardiac death (after 36 months from baseline). Nonetheless, CBT/WBT patients displayed most of
14 the negative cardiac outcomes within the first 9 months, with almost half of them (4/9) relapsing
15 during treatment sessions. On the contrary, CM participants were more likely to relapse after a longer
16 period (starting after 8 months from baseline) (Fig. 3).

17 Stratifying the sample by group allocation, we found that among CBT/WBT patients, both the
18 in-hospital (Wald= 4.235; df= 1; hazard ratio (HR)= 1.040, 95%CI: 1.002–1.079; $p = 0.040$) and the
19 6-month post-discharge (Wald= 4.594; df= 1; HR= 1.031, 95%CI: 1.003–1.060; $p = 0.032$)
20 probabilities of cardiac death, as calculated with GRACE indices, were found to predict worse cardiac
21 prognosis. On the contrary, in the CM group adverse cardiac outcomes were predicted by baseline
22 scores of depression, as assessed by CID (Wald= 5.540; df= 1; HR= 1.204, 95%CI: 1.031–1.404; $p =$
23 0.019).

24

25 **Discussion**

26

1 [As far as we could determine, this is the first RCT demonstrating a significant improvement in](#)
2 [depressive symptoms and biomarkers in patients with ACS following sequential CBT/WBT when](#)
3 [compared with CM.](#) The study provides new important clinical insights regarding the treatment of
4 depression in the setting of ACS. The sequential combination of CBT/WBT was effective in
5 significantly decreasing depressive symptoms, compared to CM. In both groups, benefits persisted at
6 follow-up, even though differences between them faded (Fig. 2). It is noteworthy the different trend
7 observed in the two groups concerning hostility, since it represents a key variable in the literature on
8 the psychological issues embedded in depressive states [29] and it has been found to play a negative
9 role on cardiac prognosis [30].

10 Medical outcomes did not differ between the two groups, yet among CBT/WBT patients
11 negative cardiac prognosis was associated with a greater severity of the cardiac illness (as indicated
12 by GRACE indexes and the timing of relapses), whereas in CM group with the severity of baseline
13 depressive symptomatology. Moreover, patients who were assigned to the treatment group displayed
14 significant decreases in the placement according to normative values of platelet count, HDL
15 Cholesterol, and D-dimer. There is evidence that these biomarkers may entail prognostic significance
16 of the occurrence of cardiovascular events [31-33].

17 The findings are important in view of the methodology that was used. Patients were not assessed
18 during hospitalization, but after one month, when stress linked to hospitalization and the impact of
19 acute illness are likely to subside and the evaluation of depressive symptoms is likely to be more
20 reliable [34]. The impact of the CBT/WBT sequential combination was not compared to treatment as
21 usual, as occurred in other studies [6], but to clinical management, where patients received the non-
22 specific elements of psychotherapy [27, 35]. Indeed, also CM yielded significant improvement in
23 affective symptoms. This indicates that non-specific support after ACS may be important, but specific
24 psychotherapeutic strategies are associated with greater benefits and underlines the need to schedule
25 booster sessions (i.e., WBT or brief CBT) in order to reinforce progresses or address potential
26 obstacles to continuance of positive changes made during the therapy.

1 WBT is a short-term psychotherapeutic strategy that emphasizes self-observation of
2 psychological well-being, with the use of structured diary, cognitive restructuring of interfering
3 thoughts and/or behaviors and homework assignments [9-10]. The working hypothesis was that
4 lifestyle changes could only be achieved with a personalized approach that targets psychological well-
5 being [9]. Based on examples taken from post-ACS everyday life, patients allocated to CBT/WBT
6 were instructed on how to overcome specific obstacles concerning lifestyle (i.e., specific strategies
7 for medication adherence, scheduling of gradual physical exercises and dietary modification
8 according to specific prescriptions following hospital guidelines). In the phase that immediately
9 follows ACS, interventions that bring the person out of negative functioning and distress may be
10 important, and this was the target of the first phase of psychotherapy (CBT). However, facilitating
11 progression toward restoration of the positive (“There is life after ACS”) and appreciation of healthy
12 lifestyle is another target that requires specific interventions (WBT). The results of this investigation
13 confirm previous studies on the role of psychotherapeutic strategies in the setting of ACS [6] and
14 provide a valid alternative/integration to pharmacological strategies, which carry the disadvantages
15 of side effects of antidepressant drugs [36-37], with particular reference to cardiovascular safety [38].
16 The sequential psychotherapeutic strategy that was used may also be applied after pharmacological
17 treatment of depression, if appropriate, and may have potential in extending therapeutic benefits
18 beyond time of medication administration, as was found to be the case in psychiatric settings [39].

19 This therapeutic approach may be potentially extended to cardiovascular rehabilitation in view
20 of the suitability of WBT for the rehabilitation process [40] and the adverse prognostic role of
21 unhealthy lifestyle and depressive symptoms in these settings [41-43]. A number of clinical situations
22 (delayed recovery after treatment, discrepancy between cardiovascular status/functioning, presence
23 of psychological comorbidity, problems with lifestyle and risky behavior, presence of stressful
24 circumstances) may be addressed by the sequential strategy we have outlined.

25 The findings of this investigation targeting psychological well-being in ACS should be seen as
26 preliminary and await proper replication studies. It should also be noted that [more than a quarter of](#)

1 [the ACS patients diagnosed with depression and/or demoralization \(36/136, 26.5%\) refused to join](#)
2 [the RCT. This percentage, however, is lower than refusal rates found in the literature on secondary](#)
3 [prevention programs, which range from 31.4% \[44\] to 72.2% \[45\] among depressed patients.](#)
4 [Moreover,](#) about half of the 740 patients initially screened by the cardiologists refused to undergo
5 psychological assessment and almost half of those who agreed refused to join the trial or retreated the
6 initial consent. The results are thus likely to reflect a self-selected population. Nonetheless, they
7 indicate a road to the practice of lifestyle medicine [44,46] that is worth perusing.

1 **Acknowledgements**

2 We thank all patients who agreed to be screened for the TREATED-ACS study and those who
3 joined the trial. In addition, we thank drs. Laura Alessi, Laura Staccini, Antonio Piolanti, Rachele
4 Ceschin, Alessandra Munno, Emanuela Offidani, Corine Panepinto, Fedra Ottolini, Letizia Riva,
5 Daniela Calabrese, Mrs. Loretta Lollini and all medical staff working at Maggiore and Molinette
6 hospitals for providing support.

7 8 **Statement of Ethics**

9 The authors assert that all procedures contributing to this work comply with the ethical
10 standards of the relevant national and institutional committees on human experimentation and with
11 the Helsinki Declaration of 1975, as revised in 2008.

12 13 ~~Disclosure Statement~~ Conflict of Interest Statement

14 The authors report no conflict of interest.

15 16 **Funding Sources**

17 This work was supported by a grant from the Compagnia di San Paolo di Torino, Italy, to
18 Professor Rafanelli.

19 20 **Author contribution**

21 C.R., G.A.D. and G.A.F. conceptualized and designed the study. C.R., S.G., G.A.D. and G.A.F.
22 collected, analyzed and interpreted the data. C.R., S.G. and G.A.F. wrote the first draft of the
23 manuscript. All the Authors critically revised the manuscript for important intellectual content. S. G.
24 performed the statistical analyses. All the Authors provided administrative, technical, or material
25 support. C.R., G.A.D. and G.A.F. supervised the whole process.

References

- 1 Carney RM, Freedland KE. Depression and coronary heart disease. *Nat Rev Cardiol.* 2017
2 Mar;14(3):145-55.
- 3 1 Rafanelli C, Roncuzzi R, Milaneschi Y, Tomba E, Colistro MC, Pancaldi LG, et al. Stressful
4 life events, depression and demoralization as risk factors for acute coronary heart disease.
5 *Psychother Psychosom.* 2005 Apr;74(3):179-84.
- 6 2 Kuhlmann SL, Arolt V, Haverkamp W, Martus P, Ströhle A, Waltenberger J, et al. Prevalence,
7 12-month prognosis, and clinical management need of depression in coronary heart disease
8 patients. *Psychother Psychosom.* 2019 Sep;88(5):300-11.
- 9 3 ~~de Figueiredo JM. Demoralization and psychotherapy: a tribute to Jerome D. Frank, MD, PhD
10 (1909–2005). *Psychother Psychosom.* 2007 Apr;76(3):129–133.~~ [de Figueiredo JM, Frank JD.
11 Subjective incompetence, the clinical hallmark of demoralization. *Compr Psychiatry.* 1982 Jul-
12 Aug;23\(4\):353-63.](#)
- 13 4 Kim JM, Stewart R, Lee YS, Lee HJ, Kim MC, Kim JW, et al. Effect of escitalopram vs placebo
14 treatment for depression on long-term cardiac outcomes in patients with acute coronary
15 syndrome: a randomized clinical trial. *JAMA.* 2018 Nov;320(20):350-8.
- 16 5 Reavell J, Hopkinson M, Clarkesmith D, Lane DA. Effectiveness of cognitive behavioral
17 therapy for depression and anxiety in patients with cardiovascular disease: A systematic review
18 and meta-analysis. *Psychosom Med.* 2018 Oct;80(8):742-53.
- 19 6 Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, et al. Effects of
20 treating depression and low perceived social support on clinical events after myocardial
21 infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD)
22 Randomized Trial. *JAMA.* 2003 Jun;289(23):3106-16.
- 23
24

- 1 8 Kubzansky LD, Huffman JC, Boehm JK, Hernandez R, Kim ES, Koga HK, et al. Positive
2 psychological well-being and cardiovascular disease: JACC health promotion series. *J Am Coll*
3 *Cardiol.* 2018 Sep;72(12):1382-96.
- 4 9 Fava GA. *Well-being therapy: Treatment manual and clinical applications.* Basel, Switzerland:
5 Karger Medical & Scientific Publishers; 2016.
- 6 10 Guidi J, Rafanelli C, Fava GA. The clinical role of well-being therapy. *Nord J Psychiatry.* 2018
7 Nov;72(6):447-53.
- 8 11 Fava GA, Rafanelli C, Grandi S, Conti S, Belluardo P. Prevention of recurrent depression with
9 cognitive behavioral therapy. *Arch Gen Psychiatry.* 1998 Sep;55(9):816-20.
- 10 12 American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders.* 4th
11 ed., revised. Washington, DC: American Psychiatric Association; 2000.
- 12 13 Fava GA, Freyberger HJ, Bech P, Christodoulou G, Sensky T, Theorell T, et al. Diagnostic
13 criteria for use in psychosomatic research. *Psychother Psychosom.* 1995;63(1):1-8.
- 14 14 Tang EW, Wong CK, Herbison P. Global Registry of Acute Coronary Events (GRACE)
15 hospital discharge risk score accurately predicts long-term mortality post-acute coronary
16 syndrome. *Am Heart J.* 2007 Jan;153(1):29-35.
- 17 15 First MB, Spitzer RL, Gibbon M, Williams J. *Structured Clinical Interview for DSM-IV-TR*
18 *Axis I Disorders, research version.* New York, NY: Biometrics Research, New York State
19 Psychiatric Institute; 2002.
- 20 16 Porcelli P, Sonino N. *Psychological Factors Affecting Medical Conditions. A New*
21 *Classification for DSM-V. Advances in Psychosomatic Medicine.* Basel, Switzerland: Karger;
22 2007.
- 23 17 Tecuta L, Tomba E, Grandi S, Fava GA. Demoralization: a systematic review on its clinical
24 characterization. *Psychol Med.* 2015 Mar;45(4):673-91.

- 1 18 Galeazzi GM, Ferrari S, Mackinnon A, Rigatelli M. Interrater reliability, prevalence, and
2 relation to ICD-10 diagnoses of the diagnostic criteria for psychosomatic research in
3 consultation-liaison psychiatry patients. *Psychosomatics*. 2004 Sep-Oct;45(5):386-93.
- 4 19 Paykel ES. The Clinical Interview for Depression: development, reliability and validity. *J*
5 *Affect Dis*. 1985 Jul;9(1):85-96.
- 6 20 Guidi J, Fava GA, Bech P, Paykel E. The Clinical Interview for Depression: a comprehensive
7 review of studies and clinimetric properties. *Psychother Psychosom*. 2011 Dec;80(1):10-27.
- 8 21 Hamilton M. Development of a rating scale for primary depressive illness. *Br J Soc Clin*
9 *Psychol*. 1967 Dec;6(4):278-96.
- 10 22 Carrozzino D, Patierno C, Fava GA, Guidi J. The Hamilton Rating Scales for Depression: a
11 critical review of clinimetric properties of different versions. *Psychother Psychosom*. 2020
12 May;89(3):133-50.
- 13 23 Kellner R. A symptom questionnaire. *J Clin Psychiat*. 1987 Jul;48(7):268-74.
- 14 24 Benasi G, Fava GA, Rafanelli C. Kellner's Symptom Questionnaire, a highly sensitive patient-
15 reported outcome measure: systematic review of clinimetric properties. *Psychother Psychosom*.
16 2020 Mar;89(2):74-89.
- 17 25 Ryff CD. Happiness is everything, or is it? Explorations on the meaning of psychological well-
18 being. *J Pers Soc Psychol*. 1989;57(6):1069-81.
- 19 26 Ryff CD. Psychological well-being revisited: Advances in the science and practice of
20 eudaimonia. *Psychother Psychosom*. 2014 Dec;83(1):10-28.
- 21 27 Guidi J, Brakemeier EL, Bockting CL, Cosci F, Cuijpers P, Jarrett RB, et al. Methodological
22 recommendations for trials of psychological interventions. *Psychother Psychosom*. 2018
23 Sep;87(5):276-84.
- 24 28 Cohen J. *Statistical power analysis for the behavioral sciences*. New York, NY: Routledge
25 Academic; 1988.

- 1 29 Brummett BH, Babyak MA, Barefoot JC, Bosworth HB, Clapp-Channing NE, Siegler IC, et al.
2 Social support and hostility as predictors of depressive symptoms in cardiac patients one month
3 after hospitalization: A prospective study. *Psychosom Med.* 1998 Nov-Dec;60(6):707-13.
- 4 30 Rafanelli C, Gostoli S, Tully PJ, Roncuzzi R. Hostility and the clinical course of outpatients
5 with congestive heart failure. *Psychol Health.* 2016 Oct;31(2):228-38.
- 6 31 von Känel R. Acute mental stress and hemostasis: when physiology becomes vascular harm.
7 *Thromb Res.* 2015 Feb;135(1):S52-5.
- 8 32 Vinholt PJ, Hvas AM, Frederiksen H, Bathum L, Jørgensen MK, Nybo M. Platelet count is
9 associated with cardiovascular disease, cancer and mortality: a population-based cohort study.
10 *Thromb Res.* 2016 Dec;148:136-42.
- 11 33 Ishida M, Itoh T, Nakajima S, Ishikawa Y, Shimoda Y, Kimura T, et al. A low early high-
12 density lipoprotein cholesterol level is an independent predictor of in-hospital death in patients
13 with acute coronary syndrome. *Intern Med.* 2019 Feb;58(3):337-43.
- 14 34 Fava GA, Sonino N. Depression associated with medical illness. *CNS Drugs.* 1996
15 Oct;5(3):175-89.
- 16 35 Fava GA, Guidi J, Rafanelli C, Rickels K. The clinical inadequacy of the placebo model and
17 the development of an alternative conceptual framework. *Psychother Psychosom.* 2017
18 Nov;86(6):332-40.
- 19 36 Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks
20 associated with the use of newer generation antidepressant drugs: a critical review of the
21 literature. *Psychother Psychosom.* 2016 Aug;85(5):270-88.
- 22 37 Fava GA, Rafanelli C. Iatrogenic factors in psychopathology. *Psychother Psychosom.* 2019
23 Jun;88(3):129-40.
- 24 38 Grace SL, Medina-Inojosa JR, Thomas RJ, Krause H, Vickers-Douglas KS, Palmer BA, et al.
25 Antidepressant use by class: association with major adverse cardiac events in patients with
26 coronary artery disease. *Psychother Psychosom.* 2018 Mar;87(2):85-94.

- 1 39 Guidi J, Tomba E, Fava GA. The sequential integration of pharmacotherapy and psychotherapy
2 in the treatment of major depressive disorder: a meta-analysis of the sequential model and a
3 critical review of the literature. *Am J Psychiatry*. 2016 Feb;173(2):128-37.
- 4 40 Nierenberg B, Mayersohn G, Serpa S, Holovatyk A, Smith E, Cooper S. Application of well-
5 being therapy to people with disability and chronic illness. *Rehab Psychol*. 2016 Feb;61(1):32-
6 43.
- 7 41 Rafanelli C, Roncuzzi R, Finos L, Tossani E, Tomba E, Mangelli L, et al. Psychological
8 assessment in cardiac rehabilitation. *Psychother Psychosom*. 2003 Nov-Dec;72(6):343-9.
- 9 42 Gostoli S, Roncuzzi R, Urbinati S, Morisky DE, Rafanelli C. Unhealthy behaviour
10 modification, psychological distress and 1-year survival in cardiac rehabilitation. *Brit J Health
11 Psychol*. 2016 Nov;21(4):894-916.
- 12 43 Gostoli S, Roncuzzi R, Urbinati S, Rafanelli C. Clinical and subclinical distress, quality of life
13 and psychological well-being after cardiac rehabilitation. *Appl Psychol Health Well Being*.
14 2017 Nov;9(3):349-69.
- 15 44 [Turk-Adawi KI, Oldridge NB, Tarima SS, Stason WB, Shepard DS. \(2014\). Cardiac
16 rehabilitation enrollment among referred patients: patient and organizational factors. *J
17 Cardiopulm Rehabil Prev. 2014 Mar-Apr;34\(2\):114-22.*](#)
- 18 45 [Zullo MD, Gathright EC, Dolansky MA, Josephson RA, Cheruvu VK, Hughes JW. The
19 influence of depression on utilization of cardiac rehabilitation post-myocardial infarction: A
20 study of 158,991 Medicare Beneficiaries. *J Cardiopulm Rehabil Prev*. 2017 Jan;37\(1\):22-9.](#)
- 21 46 Rippe JM. Are we ready to practice lifestyle medicine? *Am J Med*. 2019 Jan;132(1):6-8.

1 **Figure legends**

2

3 **Fig. 1.** CONSORT Flow Diagram of the study

4 **Fig. 2.** CID-20 total scores at different time points (Intention-To-Treat analysis)


5 **Fig. 3.** Survival curves of CBT/WBT group and CM

6

1 **Fig. 1.**


2

3



1 **Fig. 2.**

2




3

4

5

1 **Fig. 3.**



2
3

4 **LogRank (Mantel-Cox): $\chi^2= 0.809$; $df= 1$; $p= 0.368$**

5

6

1 **Table 1.** Baseline socio-demographic, medical and psychological profile of the sample.

Variables	CBT/WBT group (n = 50)	CM group (n = 50)
Age, mean (SD), y	57.64 (9.99)	60.02 (10.94)
Sex, No. (%)		
Males	31 (62)	38 (76)
Females	19 (38)	12 (24)
Marital status, No. (%)		
Single	4 (8)	7 (14)
Married	33 (66)	36 (72)
Separated	5 (10)	4 (8)
Divorced	2 (4)	1 (2)
Widow/Widower	6 (12)	2 (4)
Occupation, No. (%)		
Employed	34 (68)	24 (48)
Unemployed	1 (2)	4 (8)
Retired	13 (26)	19 (38)
Homemaker	2 (4)	3 (6)
Education, No. (%)		
Primary School	5 (10)	5 (10)
Middle School	16 (32)	18 (36)
High School	19 (38)	25 (50)
University	8 (16)	1 (2)
Post graduate education	2 (4)	1 (2)
Type of ACS, No. (%)		
STEMI acute myocardial infarction	33 (66)	33 (66)
NSTEMI acute myocardial infarction	14 (28)	13 (26)
Unstable angina	3 (6)	4 (8)
Medical procedure for ACS, No. (%)		
Single PTCA	38 (76)	39 (78)
PTCA with 2 or more stents	9 (18)	8 (16)
None	3 (6)	3 (6)
Drug-eluting Stent (DES), No. (%)	24 (51.1)	18 (38.3)
Cardiovascular (CV) risk factors, No. (%)		
Dyslipidemia	31 (62)	27 (54)
Hypertension	27 (54)	25 (50)
Smoke (current)	22 (44)	20 (40)
Familiarity	17 (34)	11 (22)
Diabetes	10 (20)	9 (18)
LVEF < 40	4 (8)	3 (6)
GRACE Risk index at admission (mortality)		
In-hospital risk, mean (SD), %	3.51 (8.58)	4.56 (7.90)
6-month risk, mean (SD), %	6.60 (11.60)	8.69 (10.57)
GRACE Risk index at admission (mortality + AMI)		
In-hospital risk, mean (SD), %	15.50 (9.85)	16.56 (10.49)
6-month risk, mean (SD), %	25.30 (12.73)	27.50 (15.00)
Medications, No. (%)		
Cholesterol reducers	49 (98)	47 (94)
Beta-blockers *	46 (92)	50 (100)
Platelet aggregation inhibitors	48 (96)	48 (96)
Cardioaspirin	47 (94)	48 (96)
Vasodilators	36 (72)	35 (70)
Angiotensin Converting Enzyme (ACE) inhibitors	31 (62)	35 (70)
Polyunsaturated fatty acids - Omega-3	11 (22)	10 (20)
Anti-hyperglycaemics	6 (12)	8 (16)
Diuretics	6 (12)	5 (10)
Angiotensin receptor blockers	5 (10)	4 (8)
Calcium antagonists *	1 (2)	6 (12)

Alpha-adrenergic receptor inhibitors *	0 (0)	4 (8)
Anti-hyperuricemics	0 (0)	2 (4)
Anti-arrhythmic	1 (2)	0 (0)
Heart rate reducers	0 (0)	1 (2)
7 or more medications, No. (%) *	11 (22)	23 (46)
Medical comorbidities, No. (%)		
Digestive system diseases	18 (36)	25 (50)
Endocrine diseases	9 (18)	5 (10)
Circulatory / cardiac comorbidities	2 (4)	4 (8)
Prostatic and male reproductive system diseases	3 (6)	2 (4)
Urinary system diseases	2 (4)	2 (4)
Orthopedic diseases	1 (2)	3 (6)
Asthma	3 (6)	1 (2)
Chronic obstructive pulmonary disease	2 (4)	1 (2)
Stroke / Aneurysm	2 (4)	1 (2)
Heteroplasia/neoplasia	2 (4)	1 (2)
Hyperuricemia	0 (0)	3 (6)
Glaucoma	1 (2)	0 (0)
Multiple sclerosis	1 (2)	0 (0)
Cluster headache	1 (2)	0 (0)
Cushing disease	1 (2)	0 (0)
Sarcoidosis	1 (2)	0 (0)
Thalassemia	0 (0)	1 (2)
Rheumatoid arthritis	0 (0)	1 (2)
2 or more medical comorbidities, No. (%)	12 (24)	13 (26)
Biomarkers		
Hemoglobin, mean (SD), g/dL	13.91 (1.21)	13.93 (1.33)
Platelet, mean (SD), 10 ³ /mmc	235.42 (57.64)	232.96 (50.20)
Creatinine, mean (SD), mg/dL	0.94 (1.78)	0.95 (0.20)
Triglycerides, mean (SD), mg/dL	115.96 (52.91)	121.69 (58.68)
HDL-C, mean (SD), mg/dL	51.98 (16.59)	46.51 (12.01)
LDL-C, mean (SD), mg/dL	87.40 (25.48)	93.96 (29.25)
Total-C, mean (SD), mg/dL	156.44 (31.07)	160.90 (37.45)
Glycated Haemoglobin, mean (SD), mmol/mol	41.20 (8.36)	42.97 (10.21)
Fibrinogen, mean (SD), mg/dL	347.84 (66.04)	356.49 (68.28)
D-dimer, mean (SD), mg/LFEU	0.68 (1.39)	0.45 (0.39)
HRV ^a , mean (SD), msec	51.10 (27.66)	41.50 (12.29)
C-reactive protein		
BO: mean (SD), mg/dL	0.19 (0.21)	0.39 (0.69)
TO: mean (SD), mg/L	0.28 (0.39)	0.64 (1.16)
Symptom Questionnaire, mean (SD)		
Anxiety	8.60 (4.73)	7.24 (4.67)
Depression	7.92 (4.77)	6.90 (4.87)
Somatization	9.82 (5.65)	7.82 (5.12)
Hostility	4.70 (4.00)	5.34 (4.36)
Psychological Well-Being scales, mean (SD)		
Autonomy	62.20 (9.18)	61.80 (9.25)
Environmental Mastery	55.28 (11.52)	55.32 (10.65)
Personal Growth *	60.48 (9.88)	56.18 (10.50)
Positive Relations with Others	61.26 (13.26)	60.20 (10.68)
Purpose in Life	56.80 (11.51)	56.22 (11.59)
Self-Acceptance	54.48 (11.63)	55.80 (13.68)
20-item Clinical Interview for Depression (CID-20), mean (SD)		
CID-20 Total score	38.18 (8.48)	36.20 (8.57)
Depression (DSM), No. (%)	35 (70)	27 (54)
Major Depression	2 (4)	3 (6)
Minor Depression	32 (64)	24 (48)
Dysthymia	1 (2)	0 (0)
History of Depression (DSM), No. (%)	34 (68)	26 (52)
Demoralization (DCPR), No. (%)	47 (94)	44 (88)
History of Demoralization (DCPR), No. (%)	36 (72)	32 (64)
Comorbidities, No. (%)		

Depression + Demoralization *	32 (64)	21 (42)
Chronicity of Depression/Demoralization, No. (%)		
Current + previous episode of Depression	26 (52)	19 (38)
Current + previous episode of Demoralization	35 (70)	31 (62)

1
2 ACS= acute coronary syndrome; AMI= acute myocardial infarction; CV= cardiovascular; DCPR=
3 diagnostic criteria for psychosomatic research; df= degrees of freedom; PTCA= percutaneous
4 transluminal coronary angioplasty;
5 BO= Bologna; TO= Torino
6 ^a *assessed only in Torino*
7 * $p \leq 0.05$

1 **Table 2.** Effects of treatment groups on psychological characteristics. All analyses were adjusted for GRACE index (6-month probability of cardiac
 2 mortality).

INTENTION-TO-TREAT (ITT) ANALYSIS											
Variable	Pre-treatment	Post-treatment	3-month follow-up	6-month follow-up	12-month follow-up	30-month follow-up	TIME*GROUP			Cohen's <i>d</i> *	Within-group scores change ^{*, a}
							<i>F</i>	<i>df</i>	<i>p</i> -value		
CBT/WBT group (n = 50), mean (SD)											
PWB Autonomy	62.20 (9.18)	64.58 (9.42)	64.54 (9.24)	64.40 (9.12)	65.50 (8.53)	64.93 (9.67)	0.173	3.846	0.948	-0.26	-2.38 (-5.51, 0.76)
PWB Environmental mastery	55.28 (11.52)	57.33 (12.93)	59.48 (11.32)	58.02 (11.83)	58.36 (12.15)	58.69 (10.97)	0.309	4.353	0.886	-0.17	-2.09 (-5.61, 1.43)
PWB Personal growth	60.48 (9.88)	61.46 (9.92)	61.95 (9.91)	60.79 (9.58)	60.55 (9.54)	59.94 (9.34)	0.982	4.253	0.420	-0.10	-0.93 (-3.91, 2.06)
PWB Positive relations	61.26 (13.26)	61.82 (13.50)	61.88 (12.86)	60.60 (13.08)	61.27 (12.08)	60.48 (11.60)	0.709	4.183	0.592	-0.04	-0.57 (-3.33, 2.19)
PWB Purpose in life	56.80 (11.51)	57.31 (11.21)	58.35 (10.09)	57.88 (10.85)	57.42 (9.81)	57.63 (9.70)	1.104	3.803	0.353	-0.04	-0.49 (-4.14, 3.17)
PWB Self-acceptance	54.48 (11.63)	55.70 (14.36)	57.59 (13.51)	55.83 (14.19)	56.66 (11.92)	56.15 (13.90)	1.593	4.325	0.170	-0.09	1.30 (-4.48, 1.89)
SQ Anxiety	8.60 (4.73)	7.04 (5.23)	6.60 (4.87)	6.67 (4.19)	6.62 (4.51)	6.00 (4.35)	1.008	4.180	0.405	0.31	1.54 (-0.10, 3.19)
SQ Depression	7.92 (4.77)	7.21 (5.42)	6.38 (5.03)	7.06 (5.22)	6.91 (5.08)	5.99 (4.64)	0.605	4.180	0.667	0.14	0.70 (-0.98, 2.37)
SQ Somatization	9.82 (5.65)	8.80 (5.73)	8.67 (5.42)	8.96 (5.02)	9.49 (5.19)	8.17 (5.00)	0.787	3.981	0.534	0.18	1.04 (-0.75, 2.84)
SQ Hostility	4.70 (4.00)	5.19 (4.96)	5.18 (4.46)	4.41 (3.71)	5.32 (4.71)	3.81 (3.37)	3.121	4.288	0.013	-0.11	-0.51 (-1.91, 0.89)
CID-20 Total score	38.18 (8.48)	29.39 (6.55)	30.48 (5.81)	29.89 (5.88)	29.70 (6.51)	30.64 (7.02)	2.748	3.853	0.030	1.16	8.73 (5.39, 12.07)
CM group (n = 50), mean (SD)											
PWB Autonomy	61.80 (9.25)	62.82 (8.77)	63.20 (8.51)	63.21 (9.00)	64.57 (9.34)	63.71 (9.26)				-0.11	-1.02 (-4.16, 2.11)
PWB Environmental mastery	55.32 (10.65)	56.69 (8.81)	57.81 (10.15)	57.51 (8.78)	58.03 (11.19)	58.81 (8.10)				-0.14	-1.33 (-4.85, 2.19)
PWB Personal growth	56.18 (10.50)	56.54 (8.70)	56.67 (9.65)	57.10 (8.90)	57.64 (10.24)	57.00 (8.85)				-0.04	-0.41 (-3.40, 2.57)
PWB Positive relations	60.20 (10.68)	59.90 (10.93)	59.93 (12.13)	58.78 (10.82)	58.95 (11.54)	60.56 (10.78)				0.03	0.31 (-2.45, 3.07)
PWB Purpose in life	56.22 (11.59)	54.97 (9.41)	55.47 (10.32)	55.96 (10.12)	55.63 (10.82)	57.76 (8.16)				0.12	1.23 (-2.42, 4.89)
PWB Self-acceptance	55.80 (13.68)	56.03 (11.52)	57.86 (12.84)	58.32 (12.39)	59.69 (13.38)	59.94 (10.52)				-0.02	-0.15 (-3.34, 3.04)
SQ Anxiety	7.24 (4.67)	6.39 (4.41)	6.13 (4.21)	7.10 (5.14)	6.33 (5.09)	5.69 (4.07)				0.19	0.87 (-0.78, 2.51)
SQ Depression	6.90 (4.87)	5.94 (4.22)	5.83 (4.75)	6.80 (5.45)	6.22 (5.09)	5.83 (4.18)				0.21	0.98 (-0.69, 2.66)
SQ Somatization	7.82 (5.12)	8.24 (4.90)	7.87 (4.58)	8.15 (5.64)	7.90 (5.38)	7.61 (4.72)				-0.08	-0.44 (-2.23, 1.36)
SQ Hostility	5.34 (4.36)	4.12 (3.78)	4.71 (3.92)	6.01 (4.73)	5.17 (4.14)	4.56 (4.11)				0.30	1.24 (-0.16, 2.64)
CID-20 Total score	36.20 (8.57)	32.30 (7.26)	31.89 (7.11)	30.59 (7.28)	30.03 (7.05)	30.30 (6.82)				0.49	3.97 (0.63, 7.31)

1 CID-20= 20-item change version Clinical Interview for Depression; CBT= Cognitive-Behavioral Therapy; CM= clinical management; df= degrees
2 of freedom; PWB= Psychological Well-Being scales; SD= standard deviation; SQ= Symptom Questionnaire; WBT= Well-Being Therapy
3 * Pre/Post-treatment scores change; ^a Values are expressed as mean difference (95% confidence interval)
4